INOVIO Form 4 — Weiner David B. (Feb. 26, 2022)
Summary
David B. Weiner, a Director of INOVIO PHARMACEUTICALS, INC. [ INO ], reports 11,667 Restricted Stock Units from a 35,000-unit award settled in Common Stock on 02/26/2022, bringing direct holdings to 868,458 shares. New grants that day were a Common Stock Option for 60,000 shares at $ 3.22, expiring 02/26/2032, vesting 15,000 shares on February 26 of 2022, 2023, 2024 and 2025, and 35,000 Restricted Stock Units vesting 11,667 shares on February 26, 2023, 11,667 on February 26, 2024 and 11,666 on February 26, 2025. The form is signed /s/ David B. Weiner, 03/01/2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“INOVIO Form 4 — Weiner David B. (Feb. 26, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ino-4-filed2022-03-01-0001055726-22-000013-369570e1c3/
, SHA-256 b4c8cdbced85cc80af10ae0ff7f33170a7ca4ef2a46b0769b76eaaef182569d3.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * Weiner David B. (Last) (First) (Middle) 660 W. GERMANTOWN PIKE SUITE 110 (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | Weiner David B. | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE | SUITE 110 | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 02/26/2022 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock | 02/26/2022 | M | 11,667 | A | (1) | 868,458 | D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Restricted Stock Unit | (1) | 02/26/2022 | M | 11,667 | (1) | (1) | Common Stock | 11,667 | $ 0 (1) | 23,333 | D Common Stock Option | $ 3.22 | 02/26/2022 | A | 60,000 | 02/26/2022 (2) | 02/26/2032 | Common Stock | 60,000 | $ 0 | 60,000 | D Restricted Stock Unit | (3) | 02/26/2022 | A | 35,000 | (3) | (3) | Common Stock | 35,000 | $ 0 (3) | 35,000 | D Explanation of Responses: 1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on February 26, 2022; 11,667 shares will vest on February 26, 2023; 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. 2. The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 26, 2022; 15,000 shares will vest on February 26, 2023; 15,000 shares will vest on February 26, 2024; 15,000 shares will vest on February 26, 2025. 3. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Remarks: /s/ David B. Weiner | 03/01/2022 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_INO_4_filed2022-03-01_0001055726-22-000013.xml
- Size
- 19,289 bytes
- SHA-256
- b4c8cdbced85cc80af10ae0ff7f33170a7ca4ef2a46b0769b76eaaef182569d3
- Original
- www.sec.gov